PureTech Health PLC PDMR Notification RSU Vesting (3178H)
July 27 2023 - 2:00AM
UK Regulatory
TIDMPRTC
RNS Number : 3178H
PureTech Health PLC
27 July 2023
27 July 2023
PureTech Health plc
PDMR Notifications
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the
"Company"), a clinical-stage biotherapeutics company dedicated to
giving life to new classes of medicine to change the lives of
patients with devastating diseases , announces that awards of
restricted share units ("RSUs") granted by PureTech on 22 July 2022
to certain non-executive directors ("PDMRs") pursuant to its
Performance Share Plan ("PSP") vested in full on 12 June 2023 the
day immediately prior to the Company's Annual General Meeting of
Stockholders . Each PDMR received vested ordinary shares on 25 July
2023 .
The Company's total issued ordinary share capital is 289,468,159
shares after the share issuance to the PDMRs, 13,264,823 shares of
which are held in treasury by the Company.
PDMR Notification
The information contained in the below notification is disclosed
in accordance with Article 19 of the EU Market Abuse
Regulation.
Details of the person discharging managerial responsibilities/person
1 closely associated
a) Name Raju Kucherlapati
John LaMattina
Robert Langer
Kiran Mazumdar-Shaw
Sharon Barber-Lui
--------------------------------- --------------------------------------------------
Reason for the notification
2
-------------------------------------------------------------------------------------
a) Position/status Non-Executive Directors
--------------------------------- --------------------------------------------------
b) Initial notification/Amendment Initial Notification
--------------------------------- --------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------------------
a) Name PureTech Health plc
--------------------------------- --------------------------------------------------
b) LEI 213800LVPDNO2Z9T9I39
--------------------------------- --------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
-------------------------------------------------------------------------------------
a) Description Ordinary Shares of PureTech Health
of the financial plc
instrument, ISIN GB00BY2Z0H74
type of instrument
--------------------------------- --------------------------------------------------
b) Nature of the Issuance of ordinary shares in settlement of
transaction certain vested RSUs under the PureTech Health
Performance Share Plan.
--------------------------------- --------------------------------------------------
c) Price(s) and Recipient Price Amount
volume(s) Raju Kucherlapati 0.01 GBP 21,507 ordinary
shares
-------- ----------------
John LaMattina 0.01 GBP 21,507 ordinary
shares
-------- ----------------
Robert Langer 0.01 GBP 21,507 ordinary
shares
-------- ----------------
Kiran Mazumdar-Shaw 0.01 GBP 21,507 ordinary
shares
-------- ----------------
Sharon Barber-Lui 0.01 GBP 21,507 ordinary
shares
-------- ----------------
--------------------------------- --------------------------------------------------
d) Aggregated Price Aggregate Volume
information- Aggregated volume 0.01 GBP 107,535 ordinary shares
------------------------
- Price
--------------------------------- --------------------------------------------------
e) Date of the 25 July 2023
transaction
--------------------------------- --------------------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--------------------------------- --------------------------------------------------
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to giving life to new classes of medicine to change the lives of
patients with devastating diseases. The Company has created a broad
and deep pipeline through its experienced research and development
team and its extensive network of scientists, clinicians and
industry leaders that is being advanced both internally and through
its Founded Entities. PureTech's R&D engine has resulted in the
development of 27 therapeutics and therapeutic candidates,
including two (Plenity(R) and EndeavorRx(R)) that have received
both US FDA clearance and European marketing authorization and a
third (KarXT) that is expected to be filed soon for FDA approval. A
number of these programs are being advanced by PureTech or its
Founded Entities in various indications and stages of clinical
development, including registration enabling studies. All of the
underlying programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and
then advanced by the PureTech team through key validation
points.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Contact:
PureTech
Investor Relations
IR@puretechhealth.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHPPUCWMUPWGQQ
(END) Dow Jones Newswires
July 27, 2023 02:00 ET (06:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024
